First Protocol Combining Ivermectin and Fenbendazole Against Cancer

Ivermectin and Fenbendazole: First Reviewed Oncology Protocol

A protocol combining ivermectin and fenbendazole has passed peer review and been published. At least, that is what the announcement attributed to Dr. Makis suggests, who claims to be seeing “incredible successes” with these repurposed drugs. The accompanying summary is specific: ivermectin attacks cancer cells by disrupting their mitochondrial function, leading to cell death via apoptosis, and blocks key energy pathways, resulting in significant tumor reduction, especially in pancreatic cancer.
It is important to separate what has been published from what has been proven: a study passing peer review does not equate to a treatment being clinically validated.

What the Protocol Says About Ivermectin and Cancer

The mechanism described is laboratory-based: disruption of mitochondrial metabolism, blockage of energy routes, and apoptosis of the tumor cell. Based on this, a relevant tumor reduction is suggested, with pancreatic cancer being the scenario where the effect would be most visible. Fenbendazole, an antiparasitic agent used in both veterinary and human medicine, completes the combination.

The sticking point is the mechanism itself. Hundreds of compounds disrupt mitochondrial function and metabolism in cancer cells, yes, but they do the same to healthy cells as well. The argument, presented without embellishment and rooted in skepticism, is that a drug killing mitochondria does not distinguish much between cell types.

From Pennies to Thousands: The Difference Between the Drugs and Chemo Sessions

This is where the economic crux lies. A dose of antiparasitic medicine costs euros; a chemotherapy session costs thousands. If the cost differential were real and accompanied by therapeutic effect, the incentive of those funding the research and setting the prices points in a different direction. This is the kind of suspicion that recurs whenever a repurposed drug emerges: cheap, known, and off-patent.

Who Truly Approves a Treatment in Spain

It is important here to clarify the decision-making chain, as it is often confused. It is not professional colleges that authorize or prohibit a therapeutic use: the Spanish Agency of Medicines and Medical Devices (AEMPS) authorizes a medication for a specific indication. Many drugs are used off-label when there is sufficient evidence, and afterward, each regional Ministry of Health guides—and in practice influences—what is prescribed within its territory. The suspicion of institutional blockage has more grounding through the issue of funding than through formal prohibition.

The Parasite Hypothesis

A tangential line runs through the discussion: antiparasitics are promising for many diseases, and this area of research is almost untouched. So-called miraculous cures have sometimes emerged from there, fueling the intuition that something might be overlooked. The reasonable doubt raised is whether some cases attributed to these drugs are actually undetected parasitic infections.

The matter reaches the exact point where it began: no one disputes that the work has been published, and no one yet provides the clinical data that would turn that announcement into a change in practice. With a cheap protocol versus expensive industry behind it, the question is not just whether it works, but who has an interest in it becoming known.

---

Disclaimer: This article summarizes a popular debate and does not constitute medical advice. Do not self-medicate. Any decision regarding cancer treatment belongs to a healthcare professional.